% | $
Quotes you view appear here for quick access.

Medivation, Inc. Message Board

  • dickeymellon dickeymellon Jun 25, 2013 4:55 PM Flag

    J&J aquisition, ARGN destroys MDVN's Xtandi in trials

    In an interview the inventor, Dr Charles Sawyers noted that ARN-509 is "more potent" than Xtandi and "might produce a higher percentage of responders or a longer duration of response." Also, ARN-509 will allow J&J to compete in earlier stages of prostate cancer with a drug that does not require the use of steroids, which has been a problem for Zytiga in treating pre-chemotherapy patients.

    Competition over pricing might also arise. At a cost of $7,450 a month, Xtandi is considerably more expensive than Zytiga, which costs around $5,500 per month. This aggressive premium pricing strategy opens the door to competitors, such as ARN-509, who may offer equally effective, but less expensive drugs.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
61.91+1.16(+1.91%)May 24 4:00 PMEDT